[{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ValiRx"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Monash University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Partners with Monash University to Support Development of Inhaled Oxytocin to Prevent Postpartum Haemorrhage","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Vectura Ltd"},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women's & Reproductive Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LUCA Science"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem\u00ae Female Infertility\/Ovarian Failure Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Creative Medical Technology"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Initiates Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Tauriga Sciences"},{"orgOrder":0,"company":"BCI Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BCI Pharma Enters Into Strategic Partnership with Mithra to Identify Novel Therapy for Endometriosis and Cancer in Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"BCI Pharma"},{"orgOrder":0,"company":"Celmatix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Celmatix"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","amount":"$30.3 million","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Raises \u00a53.86 Billion ($30.3 Million) in Oversubscribed Series B Financing","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"LUCA Science"},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","amount":"$370.0 million","upfrontCash":"$10.0 million","newsHeadline":"Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Organon"},{"orgOrder":0,"company":"Jupiter Wellness","sponsor":"Rejoy Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jupiter Wellness Signs Exclusive License Agreement With Rejoy Corporation","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jupiter Wellness"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Signs Grant Agreement to Advance Innovation in Non-Hormonal Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Bayer AG"},{"orgOrder":0,"company":"MedinCell","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dare Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dar\u00e9 Bioscience"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Vectura will support the development of a single use device/formulation combination for evaluation in Phase I of inhaled oxytocin, and then expedite technical transfer to a commercial manufacturer to advance to Phase III and commercial launch.
Because there are currently no FDA-approved vaginal diclofenac treatment options for primary dysmenorrhea, DARE-PDM1 has the potential to be a first-in-category product.
The Gates Foundation has a non-exclusive license on the product for the purposes of achieving Global Access in the target low-and middle-income countries, whilst MedinCell owns all marketing rights worldwide.
The collaboration with the Bill & Melinda Gates Foundation will contribute to expanding access to contraceptive options that address the unmet needs of women worldwide.
The product has been named JW-500 to be added to a line of other clinical stage products currently under development at the Company. Jupiter Wellness plans to file for a pre-IND meeting with the US FDA within the next 12 months and intends to seek Orphan Drug Designation.
Under the terms of the agreement, Cirqle will be responsible for conducting preclinical studies according to the mutually agreed research plan. Organon will obtain exclusive worldwide rights to develop and commercialize the asset OUI (mushroom-derived biopolymer).
Proceeds from financing will also be used to establish a robust manufacturing system based on its proprietary Mitochondrial Isolation Technology platform, a novel method for intact, shelf-stable and highly functional isolated mitochondria as a biopharmaceutical agent.
Lead AMHR2 agonist compound demonstrates high specific activity in biological assays and desired pharmacokinetic profile in preclinical animal studies.
Mithra acquired a purchase option on the rights to two development programs in innovative CSF1R kinase inhibitors, led by BCI Pharma. Under the terms of the contract, Mithra has the possibility to buy the rights to a development program on inhibitors.
The clinical trial has been planned as a prospective, double-blind, placebo-controlled study, to examine the: Effects of different Cannabidiol doses on reducing the frequency and severity of nausea in otherwise healthy pregnant women with excessive first trimester emesis.
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Contact Supplier
